This raises a theoretical concern about hypoglycemia when combined with insulin, sulfonylureas, or other glucose-lowering agents
Because AOD-9604 and the incretins act through non-overlapping mechanisms (adipose lipolysis versus incretin signaling), some research protocols examine growth-hormone-fragment and incretin approaches in combination or in parallel arms which is why AOD-9604 appears as a "frequently paired" compound alongside semaglutide and tirzepatide
However, it is banned by the World Anti-doping Agency (WADA) and may be used as a performance-enhancing drug
This pairing has shown in preclinical models to amplify NAD+ retention, leading to enhanced mitochondrial efficiency and broader anti-aging effects.[4] The Latest Breakthrough in Anti-Aging Therapy 5-Amino-1MQ is a relatively new compound, so it may be unfamiliar to many
Targeted Fat Metabolism Unlike systemic weight loss agents, AOD-9604 works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage) specifically in the areas where its applied, allowing for precise body contouring
Unlike oral supplements that lose potency through digestion, this method delivers the vitamin directly into your bloodstream for fast and effective absorption